Photo taken from: Hagop Kantarjian/X
Feb 18, 2024, 15:51
Hagop Kantarjian: In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate
Hagop Kantarjian, Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared on X:
“In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate & an acceptable safety profile in heavily pretreated adults w/ R/R B-ALL
Elias Jabbour of MD Anderson Cancer Center”
Read further.
Source: Hagop Kantarjian/X